Compare Becton Dickinson and Co (BDX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs ProShares UltraPro S&P500 — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while ProShares UltraPro S&P500 trades at $144.96. The key difference: Becton Dickinson and Co pays a 2.79% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | UPRO | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $185.39 | $150.93 |
52-Week Low | $135.49 | $89.29 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
UPRO is trading at $142.72, down 2.35% on the day, with technical indicators showing a bullish bias as moving averages signal strength while oscillators remain neutral. The stock faces immediate resistance at $145 and support at $141. Recent market sentiment reflects cautious optimism around S&P 500 performance, with analysts projecting potential index gains to 8,000 by year-end despite concerns about AI fatigue and elevated valuations.
The outlook for UPRO remains tied to broader market momentum, with earnings season potentially providing the next catalyst. Key risks include market volatility from Fed policy uncertainty and stretched valuations, while institutional positioning suggests continued confidence in large-cap US equities as the primary driver of returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
